Vericel Q4 revenue $52.7M record; net income up 31%; 2023 guidance $180-188M

Vericel Corp

2022-FY EPS reported -$0.35 revenue$164,365,000

Q4 total revenue $52.7M (+11% YoY); MACI revenue $46.3M (+24% YoY); Epicel $6.3M.
Q4 net income $5.9M ($0.12 diluted) vs $4.5M ($0.09) a year ago; adjusted EBITDA $14.9M (28% margin).
Full-year 2022 total revenue $164.4M; net loss $16.7M ($0.35 diluted); adjusted EBITDA $24.2M (15% margin).
2023 guidance: total revenue $180-188M, MACI $152-156M, burn care $28-32M, gross margin high-60%.
FDA approved NexoBrid for eschar removal; U.S. commercial launch expected Q2 2023; arthroscopic MACI on track for 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.